Is the breast-conserving treatment with radiotherapy appropriate in mutation carriers? Long-term results and review of the literature by Kirova, Youlia M. et al.
Is the breast-conserving treatment with radiotherapy
appropriate in mutation carriers? Long-term results and
review of the literature
Youlia M. Kirova, Alexia Savignoni, Brigitte Sigal-Zafrani, Anne
Rochefordiere, Re´my J. Salmon, Pascale This, Bernard Asselain, Dominique
Stoppa-Lyonnet, Alain Fourquet
To cite this version:
Youlia M. Kirova, Alexia Savignoni, Brigitte Sigal-Zafrani, Anne Rochefordiere, Re´my J.
Salmon, et al.. Is the breast-conserving treatment with radiotherapy appropriate in muta-
tion carriers? Long-term results and review of the literature. Breast Cancer Research and
Treatment, Springer Verlag, 2009, 120 (1), pp.119-126. <10.1007/s10549-009-0685-6>. <hal-
00535424>
HAL Id: hal-00535424
https://hal.archives-ouvertes.fr/hal-00535424
Submitted on 11 Nov 2010
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

CLINICAL TRIAL
Is the breast-conserving treatment with radiotherapy appropriate
in BRCA1/2 mutation carriers? Long-term results and review
of the literature
Youlia M. Kirova • Alexia Savignoni • Brigitte Sigal-Zafrani •
Anne de La Rochefordiere • Re´my J. Salmon • Pascale This •
Bernard Asselain • Dominique Stoppa-Lyonnet • Alain Fourquet
Received: 17 November 2009 / Accepted: 9 December 2009 / Published online: 24 December 2009
 Springer Science+Business Media, LLC. 2009
Abstract As tumours in BRCA1/2 mutation carriers
might be more sensitive to radiation, we investigated after
long-term follow-up whether mutation status influenced the
rate of ipsilateral and contralateral breast cancers after
breast-conserving treatment (BCT). BRCA1 and BRCA2
genes were screened for germline mutations in 131 patients
with a family history of breast and/or ovarian cancer who
had undergone BCT and radiotherapy. Patients were mat-
ched to 261 controls with sporadic breast cancer according
to age at diagnosis and year of treatment. Controls were
followed up for at least as long as the interval between
diagnosis and genetic screening in familial cases. Rates of
ipsilateral and contralateral cancer between groups were
compared by the log-rank test. The BRCA1/2 mutations
occurred in 20.6% of tested patients. Tumours in mutation
carriers were more likely to be grade III (P \ 10-4) and
oestrogen receptor negative (P = 0.005) than in non-car-
riers and controls. Overall median follow-up was
161 months. There was no significant difference in ipsi-
lateral tumours between mutation carriers, non-carriers and
controls (P = 0.13). On multivariate analysis, age was the
most significant predictor for ipsilateral recurrence
(P \ 10-3). The rate of contralateral cancer was signifi-
cantly higher in familial cases: 40.7% (mutation carriers),
20% (non-carriers), and 11% (controls) (P \ 10-4). After
13.4 years of follow-up, the rate of ipsilateral tumours was
no higher in mutation carriers than in non-carriers or
controls. As tumours in BRCA1/2 mutation carriers might
be more sensitive to radiation, BCT is a possible treatment
option.
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Introduction
BRCA1 and BRCA2 mutations are found in approximately
5% of all breast cancers and in up to 20–25% of tumours in
patients with a family history of breast and/or ovarian
cancer [1]. BRCA1 mutation carriers develop tumours of a
higher grade and proliferation index, with lower oestrogen
receptor levels than patients with no such mutation, and
tend to have worse outcomes [2–5]. BRCA2 mutation
carriers, on the contrary, present tumours with pathologic
features similar to those of sporadic tumours [2–10].
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Several studies suggest that BRCA gene mutation might
influence response to radiation therapy because tumours in
BRCA1/BRCA2 carriers are more sensitive to ionising
radiation [5–12]. The hypothesis that BRCA mutation is
associated with increased radio sensitivity was supported
by experimental and clinical data [12–19].
Breast-conserving surgery combined with radiation
therapy is standard treatment for early stage breast cancer
and provides equivalent survival to mastectomy [20–27].
We and other authors demonstrated that the recurrence rate
in BRCA1/BRCA2 carriers is not increased in this popula-
tion of patients [28–32]. On the contrary, it is well known
that after long latent period, the radiation therapy for breast
cancer can induce malignant tumours after a latency of
several years [33, 34]. The risk of second cancers in this
population of patients is insufficiently documented [35,
36]. However, its safety in BRCA mutation carriers is a
matter of debate, and several studies have compared ipsi-
lateral tumour recurrence after breast-conserving treatment
(BCT) in BRCA1 and BRCA2 mutation carriers and
patients with sporadic cancers [9, 28–32, 37–41].
As tumours in BRCA mutation carriers might be more
sensitive to radiation with increased risk of second
primaries, we report after long-term follow-up whether
mutation status influenced the rate of ipsilateral tumours
after BCT. This analysis was planned in our previously
reported study of homogeneous population of BRCA1/2
mutation carriers and their controls, treated at the Institut
Curie [28].
Patients and methods
Patients
We retrospectively analysed a cohort of women with small
breast cancers treated with breast-conserving surgery and
radiotherapy at the Institut Curie between 1981 and 2000.
These patients had been invited to attend the family cancer
clinic of our institute between 1990 and 2001 if they had a
family history of breast or ovarian cancer. Patient selection
criteria, genetic screening, and information retrieval
methods (familial history, age at cancer diagnosis and
death of relatives, and current age) have been described
earlier [28, 42].
Genetic screening was offered to women who had either
(i) two first-degree relatives affected by cancer, one with
invasive breast cancer before 41 years of age or with
ovarian cancer at any age, or (ii) at least three first- or
second-degree relatives from the same lineage affected
with invasive breast or ovarian cancer at any age. The
index case was one of the affected family members. The
probability of being a carrier of a breast cancer
predisposing allele mutation was estimated by taking into
account the segregation parameters of Claus modified by
Easton and by using the MLINK programme [43–45].
Patients were informed about the aims and limitations of
genetic screening. A blood sample was collected with their
written consent.
A total of 131 patients who had undergone conservative
surgery and radiotherapy in our institute (136 breast can-
cers) were screened. Each case was matched to two con-
trols with no family history of breast cancer. One control
had to be excluded because it did not meet our selection
criteria, giving a total of 261 sporadic cases (271 breast
tumours). Controls were randomly selected from our pro-
spective breast cancer registry of 9179 patients who
underwent conservative treatment between 1981 and 2000,
as reported earlier [28, 46]. Matching factors included age
at diagnosis, year of treatment, and period of follow-up
between cases and controls. BRCA status was known in
only one patient at diagnosis and treatment. Clinical,
pathological, and outcome data were recorded.
All the cases were treated during the same year as their
matched controls using the same protocol. Patients under-
went wide surgical excision of the primary tumour and, in
most cases, axillary lymph node dissection. This was fol-
lowed by breast irradiation and by regional node irradiation
in the cases of node involvement with doses and techniques
already described [28, 47–49]. A boost was delivered to the
tumour bed whenever indicated. Controls were followed up
for at least as long as the time between diagnosis and
genetic screening in familial cases.
Statistical analysis
Patient and tumour characteristics were compared by a chi-
square or Fisher’s exact test for qualitative variables and by
ANOVA (comparisons of means) or the Kruskal–Wallis
test (comparisons of medians) for quantitative variables.
Survival was determined from the date of diagnosis to
the date of death or last follow-up. Ipsilateral recurrence-
free interval was defined as the period from the date of
diagnosis of breast cancer to the date of the first local
recurrence. Time to recurrence was censored at the time of
any event prior to local recurrence (death, lymph node
recurrence, distant recurrence, contralateral tumour, or
second cancer) or at the time of last follow-up. The con-
tralateral tumour-free interval was defined as the period
from the date of diagnosis to the date of contralateral breast
cancer. In the 5 patients with bilateral cancer at diagnosis,
one tumour was considered to be a contralateral tumour
occurring at diagnosis (time to event equal to zero).
The Kaplan–Meier method was used to assess the
overall survival, ipsilateral recurrence-free survival and
contralateral tumour-free survival rates. Event-free survival
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times of BRCA mutation carriers, non-carriers with a his-
tory of familial breast cancer and controls with sporadic
disease were compared using the log-rank test [50, 51]. The
influence of BRCA mutation, adjusted for other prognostic
factors, was assessed in a multivariate analysis by the Cox
proportional hazards model, in a forward stepwise regres-
sion procedure [52]. Age, histological nodal status, oest-
rogen and progesterone receptor status, and Scarff–Bloom–
Richardson grading were entered into the model. Cate-
gorical variables were transformed into dummy variables
to avoid any assumption concerning the estimation of the
relative risks (RRs) between subgroups. Missing values
were coded as separate variables when necessary.
We used Splus 2000 software (MathSoft Inc., Seattle,
WA).
Results
Twenty-seven patients (20.6%) with a family history of
breast cancer had a BRCA mutation (19 BRCA1, 8 BRCA2)
(21.3% tumours). As expected, the median probability of
being a BRCA carrier was significantly higher in carriers
than in non-carriers with a family history of breast cancer
(90 [73–98] versus 55 [6–98], P = 0.002).
Patients’ characteristics were well balanced in the three
groups. Median age was 43 years [range, 26–60] in
BRCA1/2 mutation carriers, 43.5 years [24–78] in non-
carriers and 43 years [23–79] in controls (P = 0.92). The
percentage of patients who were pre-menopausal was 85,
70 and 76%, respectively (P = 0.24). As reported earlier,
the familial and sporadic cohorts were well matched with
regard to age at diagnosis [26]. Overall median follow-up
was 161 months [range 31–297] and was broken down as
follows: 167 months [35–230] for BRCA mutation carriers,
161 months [35–270] for non-carriers and 156 months
[32–297] for controls. Two BRCA1 carriers and 3 non-
carriers had synchronous bilateral breast cancers.
Table 1 gives tumour characteristics according to
BRCA1/BRCA2 mutation status. The 27 mutation carriers
had 29 tumours. These tumours were more likely to be
grade III (P \ 10-4) and receptor negative (P = 0.02) than
tumours in either non-carriers or controls, and to be of the
medullary subtype. All medullary tumours in patients with
familial cancer occurred in patients with BRCA1 mutations.
Treatment did not differ significantly amongst groups
(Table 2). The only observed difference in hormonal
treatment, probably related to hormonal status in carriers
(mostly hormonal negative tumours) was not analysed
because of the small size of patients in the three groups.
There was no significant difference in ipsilateral tumour
recurrence amongst groups (P = 0.13) nor between muta-
tion carriers and their matched controls (P = 0.43)
(Fig. 1a, b). Crude recurrence rates and hazard ratios are
given in Table 3 as well as the site of recurrence. Most
patients experienced recurrence in the same quadrant as the
initial tumour. There was no difference in site according to
group. Three of the 6 patients with medullary carcinoma
had an ipsilateral recurrence: one in the control group at
79 months and two in the mutation carrier group at 91 and
245 months. In a uni- and multivariate analysis, age was
the only significant predictor for local recurrence. The RR
of recurrence was 1.05 [1.02–1.07], (P \ 10-3) for each
decreasing year of age. BRCA mutation status, lymph node
status, hormonal receptor status and tumour grade were not
significant predictors of local recurrence.
The rate of contralateral breast cancer was significantly
higher in mutation carriers than in non-carriers and controls
(P \ 0.0001) and higher in mutation carriers than in their
matched controls (P = 0.0011) (Fig. 2a, b). There were
40.7% in the group of BRCA1/2 mutation carriers versus
20.2% in familial cases versus 11.1% in the group of
sporadic controls (P \ 10-4). In a uni- and multivariate
analysis, BRCA mutation status was the only significant
predictor for the risk of developing a contralateral cancer
(P \ 10-4). Age, lymph node status, hormonal receptor
status and tumour grade were not significant predictors.
The role of tamoxifen in the risk of contralateral breast
cancer has not been studied because of the increased
number of receptor-negative tumours.
There was no significant difference in the overall sur-
vival between the three groups (Fig. 3).
Discussion
This matched retrospective case-control single institutional
study with an overall median follow-up of 13.4 years has
shown that the rate of ipsilateral tumours was no higher in
BRCA1 and BRCA2 mutation carriers than in non-carriers
with a family history of breast cancer and in matched
controls, despite the fact that tumours with BRCA1 muta-
tions tend to be more aggressive. In order to avoid bias,
controls were followed up for at least as long as the time
interval between diagnosis and genetic screening in
familial breast cancer cases. Our study confirmed the ear-
lier reported increased incidence of contralateral breast
cancers. At the same time, there was no difference in the
overall survival in the different groups of patients. The
main weakness of our study is the limited number of
patients and its retrospective nature.
The main case–control studies on ipsilateral tumour
recurrence are summarized in Table 4. Our long-term
results support the findings of a multi-institutional study in
which no significant difference in ipsilateral recurrence
was noted between BRCA1/2 mutation carriers (n = 170)
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Table 1 Tumour
characteristics
a The medullary subtype was
more common in BRCA1
carriers than in other groups
(11.5 vs. 1.1 vs. 0.8%,
P = 0.005)
ND not determined
BRCA1/2-mutated
tumours
Non-mutated
tumours
Sporadic
controls
P
n = 29 n = 107 n = 271
T stage UICC—n (%)
No palpable tumour 3 (10.3) 17 (15.9) 49 (18.1) 0.85
T1-2 26 (89.7) 85 (79.4) 212 (78.2)
T3 0 0 1 (0.4)
Tx 0 5 (4.7) 9 (3.3)
Clinical tumour size (mm)
Median [Range] 20 [0–35] 15 [0–35] 20 [0–70] 0.49
N stage—n (%)
N0 26 (89.7) 89 (84) 243 (70.5) 0.22
N1 3 (10.3) 17 (16) 26 (29.5)
Nx
Pathological nodal status—n (%)
Negative 21 (72.4) 49 (45.8) 133 (49.1) 0.13
Positive 3 (10.3) 20 (18.7) 41 (15.1)
No lymph node dissection 5 (17.2) 38 (35.5) 97 (35.8)
Pathology—n (%)
Ductal invasive 17 (65.4) 77 (84.6) 216 (82.1) \10-3a
Lobular invasive 3 (11.5) 10 (11.0) 16 (6.1)
Medullary 3 (11.5) 1 (1.1) 2 (0.8)
Other 2 (7.7) 1 (1.1) 12 (4.5)
DCIS 1 (3.9) 2 (2.2) 17 (6.5)
ND 3 16 8
Histological grade—n (%)
I, II 9 (31.1) 67 (76.1) 166 (81.0) \10-4
III 14 (68.9) 21 (23.9) 39 (19.0)
‘non gradable’ ? ND 6 19 66
Oestrogen receptors—n (%)
Negative 11 (47.8) 19 (27.5) 33 (20.9) 0.018
Positive 12 (52.2) 50 (72.5) 125 (79.1)
ND 6 38 113
Progesterone receptors—n (%)
Negative 11 (47.8) 15 (21.7) 34 (21.7) 0.02
Positive 12 (52.2) 54 (78.3) 123 (78.3)
ND 6 38 114
Table 2 Treatment
BRCA1/2-mutated tumours Non-mutated tumours Sporadic controls P
n = 29 n = 107 n = 271
Node irradiation
No 15 (51.7) 40 (37.4) 108 (39.9) 0.40
Yes 14 (48.3) 67 (62.6) 163 (60.1)
Whole breast dose [Gy]
Median [range] 52 [45–62] 52 [43–62] 52 [45–66] 0.87
Tumour dose [Gy]
Median [range] 65 [50–75] 64 [50–78] 65 [45–82] 0.75
Boost to tumour bed (%) 72 61 66 0.6
Chemotherapy (%) 38 28 25 0.29
Hormonal therapy (%) 7 13 6 0.045
122 Breast Cancer Res Treat (2010) 120:119–126
123
and sporadic cases matched by age and date of diagnosis
(n = 469) after a median follow-up of 8.3 years, reported
by Pierce et al. [30]. Matched cohort study described
increased recurrence, after adjustment for age, in the
hereditary group at 5 years but no significant increase in
the 26 BRCA1/2 mutation carriers compared to sporadic
cases [38]. The more recent publication of the same team
reported by Brekelmans et al. [31] showed no difference in
term of ipsilateral breast recurrence, P = 0.6 between
carriers and controls. Recently published new study of very
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Fig. 1 Ipsilateral recurrence rate: a BRCA1/2 mutation carriers
versus non-carriers versus sporadic controls, b BRCA1/2 mutation
carriers versus their matched sporadic controls
Table 3 Description of ipsilateral tumours and their site
BRCA1/2-mutated
tumours
Non-mutated
tumours
Sporadic
controls
p
n = 29 n = 107 n = 271
Ipsilateral
Number 13 33 66
Hazard ratio 1.8 [1–3.3] 1.3 [0.8–2.0] 1
Site
Same quadrant 11 21 48 0.33
Other quadrant 2 12 18
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young patients by Garcia-Etienne et al. [41] suggested after
median follow-up of 4 years increased rates of ipsilateral
breast cancer incidence in mutation carriers (9.3 vs. 2.5%)
without complete information concerning the radiotherapy
modalities (total dose, boost to the tumour bed) is given.
The results of the two non-matched cohort studies in
Table 4 are contradictory, no significant difference being
found in the Robson et al. study unlike in the Haffty et al.
study of a subgroup of 127 patients under 42 years of age
[9, 37]. In the latter study, the significantly higher ipsilat-
eral recurrence rate in BRCA1/2 mutation carriers suggests
that there might be an increase in the rate of second pri-
mary cancers after 10 years. In this study and also in other
series, age was a significant predictor of recurrence, sup-
porting the observation that young age rather than BRCA
status is a strong predictive factor for local relapse in
hereditary breast cancer patients [28, 32].
We observed a significantly higher incidence of con-
tralateral breast cancer in BRCA1/2 carriers than in non-
carriers and controls. All studies of BRCA1 and/or BRCA2
mutation carriers so far have reported an increased inci-
dence of contralateral breast cancer [9, 15, 28–30, 37, 38,
40]. Pierce et al. [30] have reported 10-year actuarial
estimates of 26 and 3% for carriers and sporadic controls,
respectively (P \ 0.0001). Robson et al. [9] reported a
27% risk in carriers versus an 8% risk in non-carriers
(P = 0.002) after 10 years of follow-up. Haffty et al. [37]
recorded a 42% rate in carriers versus a 9% rate in non-
carriers (P = 0.001) at 12 years. The high risk of contra-
lateral breast cancer in BRCA1/BRCA2 mutation carriers
must be taken into account when choosing treatment. If the
choice is breast conservation, strategies such as prophy-
lactic oophorectomy and tamoxifen administration with
close radiological surveillance should be discussed with the
patient [53–55]. Mutation carriers do have a choice as no
difference has been noted in overall survival compared to
controls. The issue is complex and has been masterly
addressed in a recent article [56].
With the new advances in the knowledge of hormonal
receptor negative and HER2 negative tumours, new treat-
ment possibilities could be offered this population of
patients. The published data suggest that PARP inhibitors
could be used not only as chemo/radiotherapy sensitizers,
but also as single agents to selectively kill cancers defective
in DNA repair, specifically cancers with mutations in the
breast cancer associated (BRCA) 1 and 2 genes. This theory
of selectively exploiting cells defective in one DNA repair
pathway by inhibiting another is a major breakthrough in the
treatment of cancer. BRCA1/2 mutations are responsible for
the majority of genetic breast/ovarian cancers, known as the
hereditary breast ovarian cancer syndrome [57].
In summary, our long-term study has confirmed that the
rate of ipsilateral tumour recurrence in BRCA1 and BRCA2
mutation carriers is no higher than in non-carriers or
patients without a family history of breast cancer despite
the more aggressive features of these tumours. It has also
confirmed the higher risk of contralateral breast cancer in
mutation carriers. This calls for risk reduction strategies.
Since tumours in BRCA carriers appear to be more sensi-
tive to radiation, BCT may be considered in BRCA muta-
tion carriers after discussion with the patient.
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